KYORIN Holdings, Inc.

Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.

行业

Drug Manufacturers - Specialty & Generic

部门

Healthcare

总部

JP

首席执行官

Yutaka Ogihara

上市以来

2001年1月4日

雇员

1,982